Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ADI 100

Drug Profile

ADI 100

Alternative Names: ADI™-100

Latest Information Update: 22 Apr 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator ADiTxT Therapeutics
  • Developer Adimune; ADiTxT Therapeutics
  • Class Antihyperglycaemics; Antipsoriatics; Antispastics; DNA; Gene therapies
  • Mechanism of Action Apoptosis stimulants; Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Psoriasis; Stiff-person syndrome; Type 1 diabetes mellitus

Most Recent Events

  • 15 Apr 2025 Preclinical trials in Stiff-person syndrome in USA (unspecified route), prior to April 2025
  • 15 Apr 2025 Pharmacodynamics data from a preclinical trial in Autoimmune disorders released by Adimune
  • 14 Apr 2025 Aditxt plans for filling of clinical trial applications for psoriasis, Type 1 diabetes mellitus and Stiff-person syndrome with the German Health Authority and US FDA in the second half of 2025

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top